Use of Cemented TFNA Nail Augmentation in the Treatment of Trochanterian Rock Fractures

Sponsor
University Hospital, Brest (Other)
Overall Status
Completed
CT.gov ID
NCT04993053
Collaborator
(none)
61
1
14.9
4.1

Study Details

Study Description

Brief Summary

Intramedullary nailing is the standard treatment of trochanteric fractures. Mechanical failure such as cut-out and cut-through are associated with high rates of revision surgery, functional impairment and mortality. Augmentation of the implant have shown encouraging results in reducing the number of mechanical failures. The aim of the study was to evaluate the rate of mechanical failure of the cement augmented screws of TFNA nails.

A descriptive, retrospective, multi-operator, single-centre study was performed at our level 1 trauma centre. Patients were included if they were > 65 years of age, presented with a trochanteric fracture treated with an augmented TFNA nail. The primary outcome was fixation failure rate (cut-out or cut-through) at 3 and 6 postoperative months. Secondary endpoints were intraoperative data, clinical scores, and radiographic analysis.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    61 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Use of Cemented TFNA Nail Augmentation in the Treatment of Trochanterian Rock Fractures in Patients Over 65 Years of Age
    Actual Study Start Date :
    Jun 20, 2019
    Actual Primary Completion Date :
    Jun 3, 2020
    Actual Study Completion Date :
    Sep 15, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Fixation failure rate (cut-out or cut-through) [change at 3 and 6 postoperative months]

      On X rays

    Secondary Outcome Measures

    1. Visual Analogue Scale score [at 3 and 6 postoperative months]

      the minimum is 0 and maximum 10, higher scores mean a worse outcome.

    2. analysis evaluating quality of reduction [once]

      On X rays

    3. Augmentation volume [once]

    4. length of surgery [at 3 and 6 postoperative months]

    5. radiation exposure [once]

    6. duration of hospitalisation [once]

    7. Intraoperative adverse events [once]

    8. EuroQoL 5-Dimensions score [change at 3 and 6 postoperative months]

      the minimum is 5 and maximum 15, higher scores mean a worse outcome.

    9. Parker Mobility Score [at 3 and 6 postoperative months]

      the minimum is 0 and maximum 9, higher scores mean a better outcome.

    10. Harris Hip Score [at 3 and 6 postoperative months]

      the minimum is 0 and maximum 100, higher scores mean a betteroutcome.

    11. the tip-apex distance [once]

      On X rays

    12. TFNA screw position [once]

      On X rays

    13. distribution of cement on either side of the cervicocephalic screw [once]

      On X rays

    14. postoperative complications [at 3 and 6 postoperative months]

    15. the need for revision surgery [at 3 and 6 postoperative months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    65 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 65 years of age

    • a trochanteric fracture that occurred through a low-energy mechanism

    • an augmented TFNA nail

    Exclusion Criteria:
    • pathological fracture

    • open fracture

    • hips with pre-existing deformities other than osteoarthritis

    • a history of hip surgery

    • an insufficient quantity of injected cement (< 3 mL).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CHU de Brest Brest France 29609

    Sponsors and Collaborators

    • University Hospital, Brest

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Brest
    ClinicalTrials.gov Identifier:
    NCT04993053
    Other Study ID Numbers:
    • TFNA - 29BRC21.0076
    First Posted:
    Aug 6, 2021
    Last Update Posted:
    Aug 6, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Brest
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 6, 2021